Are AstraZeneca plc & NMC Health PLC Set To Post Stellar Returns?

Should you buy these 2 health care companies right now? AstraZeneca plc (LON: AZN) and NMC Health PLC (LON: NMC)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The health care sector continues to have huge appeal for long term investors. That’s because, while the outlook for the global economy is somewhat uncertain and growth could be pegged back by rising US interest rates and a slowing China, health care companies offer less highly correlated returns. In other words, they are less cyclical and less dependent upon the performance of the economy than most of their index peers.

Furthermore, the valuations on offer within the health care space appear to be relatively appealing. For example, AstraZeneca (LSE: AZN) currently trades on a price to earnings (P/E) ratio of just 15.7 despite being on the cusp of significantly improved financial performance.

Clearly, AstraZeneca has endured a challenging period in recent years, with a number of key, blockbuster drugs going off-patent and delivering huge falls in sales as a result of generic competition. However, AstraZeneca has freshened up its pipeline through a major acquisition programme which is still ongoing and, with the company having superb cash flow as well as a very sound balance sheet, it appears capable of taking on more debt in order to boost its long term profit potential.

In addition, AstraZeneca also offers very stable dividend payouts. In spite of its difficulties, dividends have been maintained in recent years and this means that the company continues to be a viable option for income investors.

Although its share buyback programme was cancelled when new management took over, this was a sensible step to take since that cash was better spent on improving the company’s treatment pipeline. And, with AstraZeneca forecast to return to earnings growth over the medium term, its yield of 4.2% has considerable appeal and could act as a positive catalyst on the company’s share price.

Also offering high total return potential is UAE-focused NMC (LSE: NMC). Its shares have risen by 67% since the turn of the year as investors began to factor in a stunning earnings growth rate which is set to see the company’s bottom line rise by 38% in the current year and by a further 23% next year. Despite this, NMC trades on a price to earnings growth (PEG) ratio of only 0.7 and this indicates that further share price rises are on the cards.

NMC could additionally become a very enticing income play. Certainly, its yield of 1.2% is rather low, but the company pays out just 20% of profit as a dividend. This means that dividend increases are likely to be brisk in future years – especially if the company can deliver on its highly impressive earnings guidance. And, with investor sentiment likely to remain buoyant if the global economic outlook deteriorates in the coming months, health care companies such as NMC could become increasingly popular among investors seeking high, less-cyclical growth rates.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »